Company Cerenis Therapeutics Holding Euronext Paris
Equities
FR0012616852
Biotechnology & Medical Research
Business Summary
At the end of 2023, the company boasted a portfolio of 3 products in clinical development.
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research
100.0
%
| 5 | 100.0 % | 5 | 100.0 % | -11.65% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 5 | 100.0 % | 5 | 100.0 % | -11.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 31/12/06 |
Director of Finance/CFO | - | 30/04/08 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 08/02/15 |
Chief Operating Officer | - | - | |
Laurent Guerci
PRN | Corporate Officer/Principal | - | 11/07/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 05/02/15 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 31/12/06 |
Laura Coruzzi
BRD | Director/Board Member | 71 | 26/05/15 |
Karen Noël
BRD | Director/Board Member | 51 | 08/06/17 |
Emmanuel Huynh
CHM | Chairman | 54 | 25/08/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 32,459,012 | 21,050,362 ( 64.85 %) | 253,928 ( 0.7823 %) | 64.85 % |
Company contact information
ABIONYX Pharma SA
33-43, avenue Georges Pompidou Bâtiment D2
31130, Balma
+33 5 62 24 97 06
http://www.abionyx.comSector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+16.44% | 122B | |
+18.94% | 114B | |
+19.62% | 25.71B | |
-25.37% | 19.02B | |
-20.21% | 15.83B | |
-20.20% | 15.32B | |
-47.37% | 14.88B | |
+59.91% | 14.82B | |
+4.35% | 14.1B |